Cytokinetics, Inc.: Cytokinetics to Present at the 13th Annual Needham Healthcare Conference

    Cytokinetics, Inc.: Cytokinetics to Present at the 13th Annual Needham
                            Healthcare Conference

South San Francisco, CA, April 1, 2014 - Cytokinetics, Incorporated (Nasdaq:
CYTK) announced today that Robert I. Blum, President and Chief Executive
Officer, is scheduled to present at the 13th Annual Needham Healthcare
Conference on Tuesday, April 8, 2014 at 1:40 PM Eastern Daylight Time at the
Westin Grand Central Hotel in New York, New York.
Interested parties may access the live audio webcast of this presentation by
visiting the Investor Relations section of the Cytokinetics website at
www.cytokinetics.com. The webcast replay of the presentation will be archived
on the Presentations page within the Investor Relations section of
Cytokinetics' website for two weeks following the completion of the event.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on the
discovery and development of novel small molecule therapeutics that modulate
muscle function for the potential treatment of serious diseases and medical
conditions. Cytokinetics' lead drug candidate from its cardiac muscle
contractility program, omecamtiv mecarbil, is in Phase II clinical development
for the potential treatment of heart failure. Amgen Inc. holds an exclusive
license worldwide to develop and commercialize omecamtiv mecarbil and related
compounds, subject to Cytokinetics' specified development and
commercialization participation rights. Cytokinetics is independently
developing tirasemtiv, a fast skeletal muscle activator, as a potential
treatment for diseases and medical conditions associated with neuromuscular
dysfunction. Tirasemtiv is currently the subject of a Phase II clinical trials
program and has been granted orphan drug designation and fast track status by
the U.S. Food and Drug Administration and orphan medicinal product designation
by the European Medicines Agency for the potential treatment of amyotrophic
lateral sclerosis (ALS). Cytokinetics is collaborating with Astellas Pharma
Inc. to develop CK-2127107, a skeletal muscle activator structurally distinct
from tirasemtiv, for non-neuromuscular indications. All of these drug
candidates have arisen from Cytokinetics' muscle biology focused research
activities and are directed towards the cytoskeleton. The cytoskeleton is a
complex biological infrastructure that plays a fundamental role within every
human cell. Additional information about Cytokinetics can be obtained at
www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking statements,
and claims the protection of the Act's safe harbor for forward-looking
statements. Examples of such statements include, but are not limited to,
statements relating to planned presentations, and the properties and potential
benefits of Cytokinetics' drug candidates and potential drug candidates. Such
statements are based on management's current expectations, but actual results
may differ materially due to various risks and uncertainties, including, but
not limited to, potential difficulties or delays in the development, testing,
regulatory approval and production of Cytokinetics' drug candidates and
potential drug candidates that could slow or prevent clinical development or
product approval, including risks that current and past results of clinical
trials or preclinical studies may not be indicative of future clinical trials
results and that Cytokinetics' drug candidates and potential drug candidates
may have unexpected adverse side effects or inadequate therapeutic efficacy.
For further information regarding these and other risks related to
Cytokinetics' business, investors should consult Cytokinetics' filings with
the Securities and Exchange Commission.
Contacts:
Cytokinetics, Incorporated:      
Joanna L. Goldstein 
Manager, Investor Relations & Corporate Communications
(650) 624-3000

------------------------------------------------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf
of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for
the content, accuracy and originality of the information contained therein.
Source: Cytokinetics, Inc. via Globenewswire
HUG#1773198
 
Press spacebar to pause and continue. Press esc to stop.